Direct answer
A comparison framework for ipamorelin, hexarelin and other growth hormone secretagogues across receptor selectivity and signaling assays.
- Ipamorelin and hexarelin are synthetic secretagogues studied at the growth hormone secretagogue receptor, now commonly called GHSR1a.
- Selectivity claims depend on the receptor and endpoint panel used and should not be treated as universal.
- Comparisons require matched content, full curves, receptor-null controls and consistent expression systems.
What is being compared?
Ipamorelin and hexarelin are synthetic peptides developed within growth hormone secretagogue research. They are distinct from GHRH analogues because their primary research context is the ghrelin receptor pathway rather than the GHRH receptor. Different sequences and conformational constraints can alter potency, efficacy, off-target activity and stability.
A label such as selective is always relative to the targets and endpoints tested. An early endocrine panel does not exclude every receptor, transporter or cellular effect.
How should receptor pharmacology be measured?
Use a defined GHSR1a expression system and include receptor-null parental cells. Measure full concentration-response curves for at least one proximal and one downstream endpoint if signaling bias is proposed. A reference agonist anchors plate performance, while an antagonist or genetic disruption tests receptor dependence.
Receptor density can amplify weak partial agonism and shift EC50. Report expression, species, passage and normalization. Comparing values from unrelated laboratories without these details is not a clean ranking.
Which material controls matter?
Confirm sequence and molecular mass, then prepare both compounds on the same peptide-content basis. Test solubility and recovery at the low end of each curve. Include matched vehicle and check whether counter-ion or residual solvent differs. A lower apparent potency can be a lower delivered concentration.
For endocrine models, distinguish direct receptor signaling from downstream growth hormone release and feedback. Time course and model choice determine which layer is observed.
How should findings be bounded?
The literature supports receptor and endocrine research questions, not personal administration. Health Canada specifically names ipamorelin in its 2026 warning about unauthorized online peptides. Hexarelin and related compounds should be treated with the same research-only discipline: precise identity, qualified setting and no therapeutic representation.
Continue through the evidence
Methods and quality. Peptide Dose-Response Curves: EC50, Emax and Assay Design, How to Read a Peptide Certificate of Analysis, HPLC Peptide Purity: How to Read a Chromatogram Without Overclaiming and LC-MS for Peptide Identity: Molecular Mass, Charge States and Sequence Evidence.
Connected peptide briefings. Growth Hormone Secretagogues: GHRH Analogues Versus Ghrelin Mimetics, CJC-1295 With DAC: Albumin Binding and Growth Hormone Axis Research, Research Peptides in Canada: A Laboratory Procurement Guide, Health Canada, Peptides and Research Use Only: What the 2026 Guidance Means, Shipping and Storing Research Peptides Across Canada, PT-141 and Melanotan II: Melanocortin Receptor Selectivity, BPC-157 Research: Evidence Gaps and Replication-First Study Design and GHK-Cu Research: Copper Coordination and Experimental Design.
Sources and further literature
- Ipamorelin as a selective growth hormone secretagogueFoundational comparative pharmacology paper from 1998.
- Health Canada: Think twice before injecting peptides bought onlineApril 2026 federal warning about unauthorized peptide products.
- ICH Q2(R2): Validation of Analytical ProceduresFramework for fit-for-purpose analytical procedures.
North Specs separates scientific education from product claims. Review primary literature, current regulations and institutional requirements before designing laboratory work.
